Scrip
GSK and Gilead sign Asian commercialisation deal for Viread
25 November 2009
Simon Varcoe
Please Login to read the full article.
25 November 2009
Simon Varcoe
GlaxoSmithKline has acquired the rights to commercialise Gilead Sciences' chronic hepatitis B (HBV) treatment Viread (tenofovir disoproxil fumarate) in China as part of an agreement covering four other Asian markets.
The agreement modifies the terms of a deal signed in 2002, under which GSK...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Roche's Asian partnering head looks to tap regional innovation
- Face-to-Face: Asia-Pacific emerging as the clinical trial hotspot
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
